GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IQVIA Holdings Inc (NYSE:IQV) » Definitions » EPS (Diluted)

IQV (IQVIA Holdings) EPS (Diluted) : $7.70 (TTM As of Jun. 2024)


View and export this data going back to 2013. Start your Free Trial

What is IQVIA Holdings EPS (Diluted)?

IQVIA Holdings's Earnings per Share (Diluted) for the three months ended in Jun. 2024 was $1.97. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $7.70.

IQVIA Holdings's EPS (Basic) for the three months ended in Jun. 2024 was $1.99. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 was $7.81.

IQVIA Holdings's EPS without NRI for the three months ended in Jun. 2024 was $2.64. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 was $10.51.

During the past 12 months, IQVIA Holdings's average EPS without NRIGrowth Rate was 26.30% per year. During the past 3 years, the average EPS without NRIGrowth Rate was 81.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 54.20% per year. During the past 10 years, the average EPS without NRI Growth Rate was 11.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, IQVIA Holdings's highest 3-Year average EPS without NRI Growth Rate was 81.70% per year. The lowest was -34.60% per year. And the median was 12.60% per year.


IQVIA Holdings EPS (Diluted) Historical Data

The historical data trend for IQVIA Holdings's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IQVIA Holdings EPS (Diluted) Chart

IQVIA Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.96 1.43 4.95 5.72 7.29

IQVIA Holdings Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.59 1.63 2.54 1.56 1.97

Competitive Comparison of IQVIA Holdings's EPS (Diluted)

For the Diagnostics & Research subindustry, IQVIA Holdings's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IQVIA Holdings's PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, IQVIA Holdings's PE Ratio distribution charts can be found below:

* The bar in red indicates where IQVIA Holdings's PE Ratio falls into.



IQVIA Holdings EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

IQVIA Holdings's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(1358-0)/186.300
=7.29

IQVIA Holdings's Diluted EPS for the quarter that ended in Jun. 2024 is calculated as

Diluted EPS (Q: Jun. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(363-0)/184.300
=1.97

EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IQVIA Holdings  (NYSE:IQV) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


IQVIA Holdings EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of IQVIA Holdings's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


IQVIA Holdings Business Description

Traded in Other Exchanges
Address
2400 Ellis Road, Durham, NC, USA, 27703
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Executives
Eric Sherbet officer: See Remarks 100 IMS DRIVE, PARSIPPANY NJ 07054-4235
Ari Bousbib director, officer: Chairman, CEO & Pres UNITED TECHNOLOGIES CORP, ONE FINANCIAL PLAZA, HARTFORD CT 06101
W Richard Staub officer: See Remarks
Kevin C Knightly officer: Pres Info & Tech Solutions 1499 POST ROAD, FAIRFIELD CT 06824
Panagos Constantinos officer: See Remarks 4280 EMPEROR BLVD, DURHAM NC 27703
Keriann Cherofsky officer: See Remarks 4280 EMPEROR BLVD, DURHAM NC 27703
Sheila A Stamps director C/O CIT GROUP, 1 CIT DRIVE, ATTN: GENERAL COUNSEL, LIVINGSTON NJ 07039
Morris Leslie Wims director 4280 EMPEROR BLVD, DURHAM NC 27703
John Connaughton director, 10 percent owner BAIN CAPITAL PARTNERS LLC, JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Ronald E Bruehlman officer: See Remarks C/O IQVIA HOLDINGS, INC., 83 WOOSTER HEIGHTS ROAD, DANBURY CT 06810
Ronald A Rittenmeyer director 5400 LEGACY DRIVE, PLANO TX 75024
Tpg Group Holdings (sbs) Advisors, Inc. 10 percent owner C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Michael J Evanisko director BRAUN CONSULTING, 20 W KINZIE STREET SUITE 1600, CHICAGO IL 60610
Michael R Mcdonnell officer: Chief Financial Officer C/O IQVIA HOLDINGS INC., 83 WOOSTER HEIGHTS ROAD, DANBURY CT 06810
John M. Leonard director C/O INTELLIA THERAPEUTICS INC, 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139